|
⚲
|
| Keyboard |
| Great Point Partners LLC
✚
|
|
|---|---|
| CRD # | 158423 |
| SEC # | 801-73834 |
| CIK # | 0001281446 |
| AUM | 1,777.1 M (2026-03-31) |
| Employees | 28 (82% Investors, 14% Brokers) |
| Fees | |
| Minimum | |
| Phone | 203-971-3300 |
| Address | 165 Mason Street Greenwich, CT 06830 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Apogee Therapeutics Inc | 31.5 | ||
| Vor Biopharma Inc | 31.2 | ||
| JATT Acquisition Corp | 25.1 | ||
| Amylyx Pharmaceuticals Inc | 24.3 | ||
| Nantkwest Inc | 23.0 | ||
| Nektar Therapeutics | 22.8 | ||
| Sol-Gel Technologies Ltd | 21.7 | ||
| Alumis Inc | 18.9 | ||
| Bright Minds Biosciences Inc | 16.1 | ||
| Annexon Inc | 13.8 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | GPP IV - Eutecma LLC | 2026-03-31 | 1.0 M | |
| PE | GPP IV - Lyocontract LLC | 2025-03-28 | 77.7 M | |
| PE | GPP IV - LUDI LLC | 2024-10-14 | 4.6 M | |
| PE | GPP - CF I LP | [2023-03-31] | 36.4 M | 25.6 M |
| Offered $36,415,770 · Filed 2022-12-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | GPP III - Ephicacy LLC | 2023-03-31 | 21.9 M | |
| PE | GPP III - Ixcells LLC | 2023-03-31 | 1.8 M | |
| PE | Great Point Partners IV LP | [2022-05-05] | 432.0 M | 658.5 M |
| Offered $500,000,000 · Filed 2022-04-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining $68,030,000 · Duration One year or less · Commission $680,000 · Revenue Decline to Disclose | ||||
| PE | GPP III - PCM LLC | 2022-03-31 | 40.2 M | |
| PE | GPP II-A Salmon AIV LP | 2021-02-25 | 20.6 M | |
| PE | GPP III - MLM LLC | 2021-02-25 | 5.4 M | |
| PE | Great Point Partners II Salmon AIV LP | 2021-02-25 | 67.1 M | |
| PE | GPP III - Axiom LLC | 2020-03-30 | 5.8 M | |
| PE | GPP III - Bionova LLC | 2020-03-30 | 0.1 M | |
| PE | GPP III - Tergus LLC | 2020-03-30 | 0.2 M | |
| PE | GPP II - Steripack LLC | 2020-03-30 | 32.2 M | |
| PE | Great Point Partners III-A LP | [2020-03-30] | 46.1 M | 52.7 M |
| Offered $46,100,000 · Filed 2019-08-14 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $50,000 · Duration One year or less · Revenue Not Applicable | ||||
| PE | GPP II - Masthercell LLC | 2019-03-29 | 15.0 M | |
| PE | GPP II - MDRS Holdings LLC | 2019-03-29 | 0.0 M | |
| PE | Great Point Partners III LP | [2019-03-29] | 116.2 M | 299.0 M |
| Offered $250,000,000 · Filed 2018-09-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $50,000 · Remaining $133,775,000 · Duration More than one year · Revenue Not Applicable | ||||
| PE | GPP II - UCS LLC | 2018-04-02 | 2.2 M | |
| PE | GPP II - ABR LLC | 2017-03-31 | 0.1 M | |
| PE | GPP I - Ah LLC | 2016-04-29 | 0.7 M | |
| PE | GPP I - Cytovance LLC | 2016-04-29 | 0.0 M | |
| PE | GPP I - PCF LLC | 2016-04-29 | 0.0 M | |
| PE | GPP - OHS LLC | 2016-03-29 | 0.0 M | |
| PE | GPP II-Corrona LLC | 2015-03-30 | 1.5 M | |
| PE | GPP II - Salmon Co-Invest LP | 2015-03-30 | 2.2 M | |
| PE | GPP II Offshore Feeder LP | 2014-03-31 | ||
| PE | Great Point Partners II-A LP | [2014-03-31] | 139.6 M | 6.6 M |
| Offered $200,000,000 · Filed 2013-07-25 (D) · Exemption 506, 3(c), 3(c)(7) · Remaining $60,430,000 · Duration One year or less · Revenue Not Applicable | ||||
| PE | GPP - Connecture LLC | 2013-08-23 | 0.2 M | |
| PE | GPP I - BNN LLC | 2013-08-23 | 3.9 M | |
| PE | GPP I - HSI LLC | 2013-08-23 | 2.0 M | |
| PE | GPP I - PPT LLC | 2013-08-23 | 1.1 M | |
| PE | Great Point Partners II LP | [2013-03-28] | 150.3 M | 21.7 M |
| Offered $200,000,000 · Filed 2013-10-01 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $49,680,000 · Duration One year or less · Commission $71,250 · Revenue Not Applicable | ||||
| HF | Biomedical Institutional Value Fund LP | 2012-02-14 | 4.2 M | |
| HF | Biomedical Offshore Value Fund Ltd | [2012-02-14] | 772.3 M | 178.8 M |
| Filed 2025-12-17 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Biomedical Value Fund LP | [2012-02-14] | 50.7 M | 381.4 M |
| Filed 2021-12-20 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Great Point Partners I LP | 2012-02-14 | 27.7 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 17 | 1.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 17 | 1.8 |
| By Discretionary | ||
| Discretionary | 17 | 1.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 17 | 1.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.2 | |
| United States Persons | 1.6 | |
| Total | 17 | 1.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Riyaz Nooruddin | Director | 61 | 22 | |
| Alan Kelly | Director | 39 | 17 | |
| Charl Grobler | Director | 7 | 5 | |
| Jeffrey Jay | Director, Executive Officer | 12 | 2 | |
| David Kroin | Executive Officer | 7 | 2 | |
| Great Point Partners LLC | Executive Officer, Promoter | 3 | 2 | |
| Great Point GP LLC | Executive Officer | 2 | 2 | |
| Great Point Partners CF I GP LLC | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001281446] | |
| 13F-NT | [0001281446] | |
| 3 | [0001281446] | |
| 4 | [0001281446] | |
| SC 13D | [0001281446] | |
| SC 13G | [0001281446] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.9B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Adamas Pharmaceuticals Inc ADMS
Common Stock
|
2017-06-21 | Sell | 10,000 | $17.44 | 174,400 |
|
Adamas Pharmaceuticals Inc ADMS
Common Stock
|
2017-06-20 | Sell | 20,000 | $17.35 | 347,000 |
|
Adamas Pharmaceuticals Inc ADMS
Common Stock
|
2017-06-19 | Sell | 350,000 | $17.05 | 5,967,500 |
|
Connecture Inc CNXR
Common Stock
|
2015-06-30 | Gift | 10,000 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 1,375,733 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 39,703 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 47,235 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 36,493 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 28,696 | $0.00 | |
|
Apyx Medical Corp BVX
Series B Convertible Preferred Stock · derivative
|
2015-03-17 | Grant | 3,588,139 | ||
|
Apyx Medical Corp BVX
Common Stock
|
2015-03-17 | Grant | 480,000 | $2.50 | 1,200,000 |
|
Apyx Medical Corp BVX
Common Stock Warrants (right to buy) · derivative
|
2015-03-17 | Disposed to issuer | 5,250,000 | ||
|
Apyx Medical Corp BVX
Series A Convertible Preferred Stock · derivative
|
2015-03-17 | Disposed to issuer | 3,500,000 | ||
|
Connecture Inc CNXR
Series B Preferred Stock · derivative
|
2014-12-17 | Conversion | 17,696,553 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2014-12-17 | Sell | 395,886 | $8.00 | 3,167,088 |
|
Connecture Inc CNXR
Common Stock
|
2014-12-17 | Conversion | 5,898,851 | ||
|
Apyx Medical Corp BVX
Stock Option (Option to Buy) · derivative
|
2014-07-17 | Grant | 12,000 | $0.00 | |
|
WaferGen Bio-systems Inc WGBS
Common Stock
|
2013-11-15 | Conversion | 899,893 | ||
|
WaferGen Bio-systems Inc WGBS
Common Stock
|
2013-11-15 | Conversion | 899,893 | ||
|
WaferGen Bio-systems Inc WGBS
Series 1 Convertible Preferred Stock · derivative
|
2013-11-15 | Conversion | 357.76 | ||
| showing 20 of 39 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
D2 Asset Management LP
✚
|
TX | 1,825.9 M |
|
ParaFi Capital LP
✚
|
NY | 1,817.8 M |
|
Tensile Capital Management LP
✚
|
CA | 1,796.0 M |
|
Morgan Creek Capital Management LLC
✚
|
NC | 1,790.2 M |
|
QVT Financial LP
✚
|
NY | 1,786.7 M |
|
Alta Park Capital LP
✚
|
CA | 1,779.6 M |
|
OFS Capital Management LLC
✚
|
IL | 1,760.0 M |
|
RCF Management LLC
✚
|
CO | 1,757.0 M |
|
Parkman Healthcare Partners LLC
✚
|
CT | 1,744.0 M |
|
Long Path Partners LP
✚
|
CT | 1,732.8 M |